
    
      The duration of the study for an individual patient is at least 40 weeks and will include a
      period to assess eligibility (screening period) of up to 4 weeks (28 days), a treatment
      period of up to 8, 28-day cycles (32 weeks), and a follow-up visit 30 days following the last
      administration of study drug. Treatment may continue if the patient is deriving benefit and
      does not experience disease progression, unacceptable toxicity, or meet other study
      withdrawal criteria.

      Per Protocol Amendment No. 5, accrual of patients with essential thrombocythemia is closed.
    
  